<DOC>
	<DOCNO>NCT01117129</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , parallel group study assess efficacy safety rituximab [ MabThera/Rituxan ] patient severe active rheumatoid arthritis refractory least one anti-TNF treatment , use magnetic resonance imaging ( MRI ) hand efficacy measurement . Patients randomize receive 2 intravenous infusion 14 day apart either 1000mg MabThera ( group A ) placebo ( group B ) . All patient receive methotrexate 10-25mg weekly . Patients group A demonstrate clinical response week 24 may receive cycle MabThera , patient group B without clinical response also treat active MabThera . Anticipated time study treatment 2 year . Target sample size &lt; 50 patient .</brief_summary>
	<brief_title>A Study Efficacy Rituximab Mabthera/Rituxan Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging Hand ( RESONAR )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , 1875 year age active rheumatoid arthritis ( DAS28CRP &gt; 3.2 ) refractory one antiTNF stable treatment RA &gt; /=4 week evidence erosive disease and/or synovitis wrist and/or knuckle active systemic local infection previous current history demyelinization process central nervous system , pancytopenia aplasic anaemia sign immunodeficiency , HIV infection tuberculosis contraindication MRI , metal device , claustrophobia , moderate severe renal insufficiency , allergy contrast agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>